Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria Pancreatectomised patients~* Caucasians above 18 years of age who have undergone total pancreatectomy~* Normal haemoglobin~* Informed consent Healthy subjects~* Normal fasting plasma glucose (FPG) and normal HbA1C (according to the World Health Organization (WHO) criteria)~* Normal haemoglobin~* Age above 18 years~* Informed consent~Exclusion criteria Pancreatectomised patients~* Inflammatory bowel disease~* Operation within the last 3 months~* Ongoing chemotherapy or chemotherapy within the last 3 months~* Ostomy~* Nephropathy (serum creatinine \>150 µM and/or albuminuria)~* Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) \>3×normal values)~* Pregnancy and/or breastfeeding~* Age above 80 years~* Any condition that the investigator feels would interfere with trial participation Healthy subjects~* Diabetes mellitus (DM)~* Prediabetes (impaired glucose tolerance and/or impaired FPG)~* First degree relatives with DM~* Inflammatory bowel disease~* Intestinal resection and/or ostomy~* Nephropathy (serum creatinine \>150 µM and/or albuminuria~* Liver disease (ALAT and/or serum ASAT \>2×normal values)~* Pregnancy and/or breastfeeding~* Age above 80 years~* Any condition that the investigator feels would interfere with trial participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Pancreatectomised + Lixisenatide (Type: ACTIVE_COMPARATOR): During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously
- Pancreatectomized + lixisenatide-placebo (Type: PLACEBO_COMPARATOR): During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously.
- Healthy + Lixisenatide (Type: ACTIVE_COMPARATOR): During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously
- Healthy + lixisenatide-placebo (Type: PLACEBO_COMPARATOR): During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g \[U-13C6\]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete